Collegium Pharmaceutical (NASDAQ:COLL) Announces Earnings Results, Beats Expectations By $0.09 EPS

Collegium Pharmaceutical (NASDAQ:COLL) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09, Zacks reports. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Collegium Pharmaceutical updated its FY 2025 guidance to EPS.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded up $0.07 during trading on Thursday, reaching $28.42. 536,982 shares of the stock were exchanged, compared to its average volume of 420,678. Collegium Pharmaceutical has a 12 month low of $28.11 and a 12 month high of $42.29. The firm has a market cap of $916.55 million, a PE ratio of 12.25 and a beta of 0.82. The stock has a 50-day moving average price of $30.88 and a 200-day moving average price of $33.55. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.